[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:mecp2-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"MECP2 Gene",13,11,[8,16,22,28,35,41,47,53,59,65,71,77,84],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07503444","A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome",[12],"Phase 3","RECRUITING","2026-08-26T02:18:29.369233Z","2026-05-29T15:36:40.189674Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07480564","Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to \u003C4 Years With Rett Syndrome",[12],"2026-08-03T03:01:15.394071Z","2026-05-29T15:36:40.188848Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT06840496","To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome",[12],"2026-08-26T02:18:04.640417Z","2026-05-05T02:43:28.868672Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":33,"content_modified":34},"NCT06430385","ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)",[32],"Phase 1\u002FPhase 2","2026-08-26T02:17:26.640202Z","2026-05-05T02:35:31.869425Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT07569445","Auditory EEG and Behavioral Assessments in Individuals With Rett Syndrome",[],"2026-08-26T02:15:46.655893Z","2026-05-13T02:55:06.732644Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT06338267","Validating Innovative Biosensors for Rett Autonomic Symptom Tracking",[],"2026-08-26T02:18:48.678868Z","2026-05-13T02:55:06.436426Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT05932589","Neurophysiologic Biomarkers in Rett Syndrome",[],"2026-08-26T02:15:34.659160Z","2026-05-13T02:55:06.395026Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT05432349","Rett Syndrome Registry",[],"2026-08-26T02:15:00.557154Z","2026-05-13T02:55:06.348215Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT04900493","The Rett Syndrome Global Registry",[],"2026-08-26T02:17:39.857430Z","2026-05-13T02:55:06.273186Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":69,"content_modified":70},"NCT06585605","A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes",[],"2026-08-26T02:17:50.500039Z","2026-06-02T11:21:24.705937Z",{"nct_id":72,"title":73,"phases":74,"status":13,"updated_at":75,"content_modified":76},"NCT06967727","Registry and Natural History of Epilepsy-Dyskinesia Syndromes",[],"2026-08-26T02:18:36.226508Z","2026-05-13T02:55:06.602470Z",{"nct_id":78,"title":79,"phases":80,"status":81,"updated_at":82,"content_modified":83},"NCT05898620","A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T01:57:36.164517Z","2026-05-05T02:43:28.567314Z",{"nct_id":85,"title":86,"phases":87,"status":81,"updated_at":88,"content_modified":89},"NCT05606614","A Phase 1\u002F2\u002F3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)",[12],"2026-08-03T02:05:00.744226Z","2026-05-05T02:43:28.301389Z"]